Pharmaceutical compositions of estrogenic agents

1. A pharmaceutical composition comprising, by weight:

a) from about 2% to about 8% 1-[4-(2-Azepan-1yl-ethoxy)-benzyl]-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol or 2-(4-Hydroxy-phenyl)-3-methyl-1-(4-(2-piperidin-1-yl-ethoxy)benzyl]-1H-indol-5-ol, or a pharmaceutically acceptable salt thereof;

b) lactose from about 32% to about 38%;

c) microcrystalline cellulose from about 32% to about 38%;

d) pregelatinized starch from about 12% to about 16%;

e) ascorbic acid from about 1% to about 2%;

f) sodium lauryl sulfate from about 1% to about 2%;

g) sodium starch glycolate from about 4% to about 8%;

h) silicon dioxide from about 0.1% to about 0.2%; and

i) magnesium stearate from about 0.3% to about 0.7%.

2. A pharmaceutical composition comprising, by weight:

a) from 0.1% to 25% 1-[4-(2-Azepan-1yl-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-1H-indol-5-ol or 2-(4-Hydroxy-phenyl)-3-methyl-1-(4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indol-5-ol, or a pharmaceutically acceptable salt thereof;

b) from about 20% to about 80% lactose;

c) from about 4% to about 40% pregelatinized starch;

d) from about 0.2% to about 5% sodium lauryl sulfate;

e) from about 0.5% to about 15% ascorbic acid;

f) from about 0.1% to about 10% silicon dioxide; and

g) from about 0.2% to about 10% magnesium stearate.

3. A pharmaceutical composition of claim 2 comprising, by weight:

a) from about 5% to about 18% 1-[4-(2-Azepan-1yl-ethoxy)-benzyl]-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol or 2-(4-Hydroxy-phenyl)-3-methyl-1-(4-(2-piperidin-1-yl-ethoxy)benzyl]-1H-indol-5-o l, or a pharmaceutically acceptable salt thereof;

b) from about 47% to about 77% lactose;

c) from about 25% to about 35% pregelatinized starch;

d) from about 1% to about 2% sodium lauryl sulfate;

e) from about 1% to about 3% ascorbic acid;

f) from about 0.1% to about 0.5% silicon dioxide; and

g) from about 0.2% to about 0.5% magnesium stearate.